不同脊髓灰质炎加强疫苗所赋予的黏膜与全身免疫及保护的长期评估
研究在小鼠中比较植物来源的脊髓灰质炎加强疫苗与灭活脊髓灰质炎疫苗(IPV)加强的黏膜与全身免疫及中和抗体保护。小鼠经IPV皮下基础免疫后口服含1μg或25μg脊髓灰质炎病毒蛋白1(VP1)的冻干植物细胞加强。含VP1及植物来源佐剂的植物加强疫苗可诱导高且持久的VP1-IgG1、IgA和中和抗体滴度,并对三个血清型提供相同水平保护。
要点
- 单剂或双剂IPV免疫一年后VP1-IgG1滴度降至背景水平。
- 双剂IPV对1型血清型血清阳性率下降>50%,单剂<10%。
- 含VP1及植物佐剂的植物加强疫苗维持高滴度并保护所有三个血清型。
核心结论
- 表达VP1的冻干植物细胞可无需冷链储存而不失效力,该无病毒、无冷链疫苗已准备好进一步临床开发。
研究设计与样本
- 小鼠经IPV皮下基础免疫后,口服含1μg或25μg脊髓灰质炎病毒蛋白1(VP1)的冻干植物细胞加强,每月一次共三个月,或首次基础免疫一年后单次加强。
主要发现
- 单剂或双剂IPV免疫一年后VP1-IgG1滴度降至背景水平,双剂IPV对1型血清型血清阳性率下降>50%,单剂<10%。
- 单剂IPV对1型和2型血清型无保护或保护极小,但对3型血清型有保护。
- 单剂或双剂IPV免疫小鼠的VP1-IgA滴度可忽略不计。
- 含VP1及两种植物来源佐剂的植物加强疫苗诱导显著高且持久的VP1-IgG1、IgA和中和抗体滴度(平均4.3-6.8 log2滴度)。
- 含VP1及植物来源佐剂的植物加强疫苗在29至400天维持相同水平滴度,并在整个研究期间对全部三个血清型提供相同水平保护;即使约260天未给予植物加强,VP1-IgG1滴度仍维持高水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral polio vaccine (OPV) and Inactivated Polio Vaccine (IPV) have distinct advantages and limitations. IPV does not provide mucosal immunity and introduction of IPV to mitigate consequences of circulating vaccine-derived polio virus from OPV has very limited effect on transmission and OPV campaigns are essential for interrupting wild polio virus transmission, even in developed countries with a high coverage of IPV and protected sewer systems. The problem is magnified in many countries with limited resources. Requirement of refrigeration for storage and transportation for both IPV and OPV is also a major challenge in developing countries. Therefore, we present here long-term studies on comparison of a plant-based booster vaccine, which is free of virus and cold chain with IPV boosters and provide data on mucosal and systemic immunity and protection conferred by neutralizing antibodies. Mice were primed subcutaneously with IPV and boosted orally with lyophilized plant cells containing 1μg or 25μg polio viral protein 1 (VP1), once a month for three months or a single booster one year after the first prime. Our results show that VP1-IgG1 titers in single or double dose IPV dropped to background levels after one year of immunization. This decrease correlated with >50% reduction in seropositivity in double dose and <10% seropositivity in single dose IPV against serotype 1. Single dose IPV offered no or minimal protection against serotype 1 and 2 but conferred protection against serotype 3. VP1-IgA titers were negligible in IPV single or double dose vaccinated mice. VP1 antigen with two plant-derived adjuvants induced significantly high level and long lasting VP1-IgG1, IgA and neutralizing antibody titers (average 4.3-6.8 log2 titers). Plant boosters with VP1 and plant derived adjuvants maintained the same level titers from 29 to 400days and conferred the same level of protection against all three serotypes throughout the duration of this study. Even during period, when no plant booster was given (∼260days), VP1-IgG1 titers were maintained at high levels. Lyophilized plant cells expressing VP1 can be stored without losing efficacy, eliminating cold chain. Virus-free, cold-chain free vaccine is ready for further clinical development.
引用
- Xiao Y, Daniell H. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines. Vaccine. 2017. PMID: 28111147. doi:10.1016/j.vaccine.2016.12.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。